New study shows blood test detected cancer metastasis

Research by Chronix Biomedical and Institute of Veterinary Medicine Gottingen highlights cell-free DNA analysis for cancer minimal residual disease

2013-10-01

(Press-News.org) San Jose, CA and Göttingen, Germany -- Researchers from the University Göttingen Institute of Veterinary Medicine and Chronix Biomedical have published a new study exploring the genetic hallmarks of canine mammary cancer. Appearing in the peer-reviewed journal PLOS ONE, the paper identifies important similarities and differences between human and canine breast tumors, providing a strong platform for future research using the canine model system. (Note to Editors: The paper is accessible here.)

As part of the project, the research team successfully implemented Chronix Biomedical's innovative protocol for detecting tumor DNA found in the cell-free portion of blood, and thus demonstrating the power of this application for monitoring minimal residual disease in cancer. The data generated provides a personalized readout of cancer genotype in each individual patient and can be used to track disease progression both pre- and post-treatment.

Tracking cancer status

The research team analyzed five canine mammary carcinomas in the study. Each was shown to exhibit gross chromosome instability, similar to those observed in human breast cancer samples. These variations included chromosomal and segmental copy-number changes in several well-described cancer genes, such as cMYC, MYB, CFA1, and HER2/ERBB2. However, a recurrent deletion of the proximal part of chromosome 27 that contains the tumor suppressor gene PFDN5, which is so far not described as recurrently deleted in human breast cancer, also had been detected. The researchers found the deletion in 50 percent of the 20 canine carcinomas that were analyzed.

Perhaps most remarkable, the researchers were able to use cell-free DNA (cfDNA) analyses to detect and measure the occurrence of specific chromosomal breakpoints in blood plasma. The first step of the process involves massively parallel sequencing to detect unusual chromosome rearrangements, the likes of which are the hallmark of cancer cells. These can then be reliably detected and quantified subsequently using highly sensitive digital PCR. The combined approach is a very cost-effective option for tracking tumor progression or recurrence.

Dr. Julia Beck, Senior Scientist at Chronix Biomedical and first author of the study, commented: "We were able to detect the persistence of a plasma tumor marker after surgery in one of the canine patients, directing veterinarians to schedule a tomographic examination that revealed metastatic lesions in the lung. We're confident that the same approach could be reliably used to analyze human blood samples."

Prof. Dr. Bertram Brenig, director of the Institute of Veterinary Medicine at the University of Göttingen and co-author of the study, feels confident that the results of the study will have remarkable impact on the future decisions regarding the therapy of mammary tumors in dogs. Commenting, he said, "This minimally invasive diagnostic tool offers the great opportunity to identify potential tumor development in at-risk patients at an early stage and follow up the progress after surgery."

Extending the cfDNA approach to human cancer

Although cancer treatments have improved significantly over the last few decades, several hurdles remain to be overcome. Currently, no methods can accurately differentiate between those patients exhibiting a significant response to treatment and those still harboring residual cancer cells. This means that further treatments must be routinely performed on all patients, often unnecessarily.

To improve the effectiveness of cancer treatment and minimize patient suffering, Chronix Biomedical is already extending its studies using cfDNA to assessing tumor status in human samples. Chronix Biomedical has developed a cfDNA blood test to monitor minimal residual disease in most cancers that will enable physicians to make informed treatment decisions based on both the unique genetic makeup of each patient's tumor, and the likelihood that the tumor is still present after therapy.

Chronix Biomedical's Chief Technology Officer and senior author of the study, Ekkehard Schütz, M.D., Ph.D., is confident that the approach has great potential for providing quantitative data on tumor incidence, without the need for invasive biopsies. Commenting on the study, Dr. Schütz said: "Our results so far indicate that cfDNA can provide a powerful means of assessing tumor status as a 'liquid biopsy', both at the earliest stages of cancer development and following treatment or surgery. Such diagnostic information could be a powerful means of improving treatment outcome."

"We have already seen some very positive results using our minimal residual disease blood tests," said Howard Urnovitz, Ph.D., CEO of Chronix Biomedical, whose team recently collaborated with The University of Texas MD Anderson Cancer Center to present preliminary data from their research at the American Society of Clinical Oncology Annual Meeting 2013. "By providing a means of tracking the body's response to treatment, we expect these tests to enhance patient care, while also greatly reducing the cost to the healthcare system."

###

About Chronix Biomedical

Chronix Biomedical is a molecular diagnostics company developing blood tests primarily for cancer, including companion diagnostics and tests for detecting minimal residual disease. Chronix is preparing to offer its pioneering tests through its own laboratories under CLIA certification. The Company's initial product is a test to be used by cancer treatment centers and oncologists in the treatment of cancer patients. Chronix Biomedical is privately held with headquarters in San Jose, California, and laboratories in Göttingen, Germany and Brookings, South Dakota. It was the first Company to use next-generation sequencing on cell-free DNA. The Company has two issued patents on the detection of cell-free DNA and RNA, and four patents pending using next-generation sequencing technology for the detection of breast cancer, prostate cancer and colorectal cancer. For additional information please visit http://www.chronixbiomedical.com.

ELSE PRESS RELEASES FROM THIS DATE:

Leisure-time exercise could lower your risk of high blood pressure

2013-10-01

Physical activity in your leisure time could help keep your blood pressure at a healthy level, new research in the American Heart Association journal Hypertension suggests. Researchers pooled results from 13 studies on the effects of physical activity on blood pressure. The studies involved 136,846 people in the United States, Europe or East Asia who initially had healthy blood pressure. More than 15,600 later developed high blood pressure during follow-up periods ranging from two to 45 years. People who exercised more than four hours per week in their leisure time had ...

Finding the place where the brain creates illusory shapes and surfaces

2013-10-01

The logo of the 1984 Los Angeles Olympics includes red, white and blue stars, but the white star is not really there: It is an illusion. Similarly, the "S" in the USA Network logo is wholly illusory. Both of these logos take advantage of a common perceptual illusion where the brain, when viewing a fragmented background, frequently sees shapes and surfaces that don't really exist. "It's hallucinating without taking drugs," said Alexander Maier, assistant professor of psychology at Vanderbilt University, who headed a team of neuroscientists who has pinpointed the area ...

Secrets of Antarctic extremohiles that survive in cold salty water

2013-10-01

SYDNEY: A team led by scientists at the University of New South Wales has uncovered the genetic secrets of "extremophile" microbes that can survive in water temperatures as low as minus 20 degrees in the saltiest lake in Antarctica. Deep Lake, about five kilometres from Davis Station, was formed about 3500 years ago, when the Antarctic continent rose, isolating a section of ocean. The water in the 36-metre deep lake is now so salty it remains in liquid form down to a temperature of minus 20 degrees. "The lake has the distinction of being the least productive lake ever ...

Concerns over mercury levels in fish may be unfounded

2013-10-01

New research from the Children of the 90s study at the University of Bristol suggests that fish accounts for only seven per cent of mercury levels in the human body. In an analysis of 103 food and drink items consumed by 4,484 women during pregnancy, researchers found that the 103 items together accounted for less than 17 per cent of total mercury levels in the body. Concerns about the negative effects of mercury on fetal development have led to official advice warning against eating too much fish during pregnancy. This new finding, published today in Environmental Health ...

Stanford-developed technique induces egg growth in infertile women, and 1 gives birth

2013-10-01

STANFORD, Calif. — Researchers at the Stanford University School of Medicine have identified a way to induce the ovaries of some infertile women to produce eggs. Using the technique, clinicians at the St. Marianna University School of Medicine in Kawasaki, Japan, collected viable eggs from five women with a condition called primary ovarian insufficiency. One of these women has given birth to a healthy baby, and another is pregnant. Twenty-seven women in Japan took part in the experimental study. The researchers were able to collect mature eggs for in vitro fertilization ...

When ICUs get busy, doctors triage patients more efficiently, Penn study finds

2013-10-01

PHILADELPHIA— A new study by Penn Medicine researchers published Oct. 1 in the Annals of Internal Medicine found that busy intensive care units (ICUs) discharge patients more quickly than they otherwise would and do so without adversely affecting patient outcomes – suggesting that low-value extensions of ICU stays are minimized during times of increased ICU capacity strain. An expected growth in the number of patients requiring critical care resources combined with a projected shortage in critical care providers will likely result in ICUs operating under conditions of ...

Less blood clot risk is linked to estradiol than to Premarin pills

2013-10-01

SEATTLE—Women can choose among several types of estrogen pills, which are equally effective at relieving menopausal symptoms. But in an observational study of comparative safety, use of estradiol was associated with less risk of developing blood clots in leg veins (deep vein thrombosis) and clots in the lungs (pulmonary emboli) than was use of conjugated equine estrogens. According to a joint University of Washington (UW)–Group Health study in JAMA Internal Medicine, women patients of Group Heath who were prescribed a generic version of estradiol—a bio-equivalent estrogen—experienced ...

Study compares 2 commonly used estrogen drugs and cardiovascular safety

2013-10-01

The oral hormone therapy conjugated equine estrogens (CEEs), which is used by women to relieve menopause symptoms, appears to be associated with increased risk for venous thrombosis (VT, blood clots) and possibly myocardial infarction (heart attack), but not ischemic stroke risk, when compared with the hormone therapy oral estradiol, according to a study published by JAMA Internal Medicine, a JAMA Network publication. Researchers compared the cardiovascular safety of the two commonly used oral estrogen medications because little is known about the cardiovascular safety ...

Massachusetts primary care malpractice claims related to alleged misdiagnoses

2013-10-01

Most of the primary care malpractice claims filed in Massachusetts are related to alleged misdiagnoses, according to study by Gordon D. Schiff, M.D., of the Harvard Medical School and Brigham and Women's Hospital, Boston, and colleagues. The focus for improving patient safety and malpractice risk is increasingly on outpatient care, according to the study background. Researchers examined the types, causes and outcomes of primary care malpractice claims by studying closed (resolved) claims data from two Massachusetts insurance carriers that covered most of the state's ...

Study finds continual increase in bed sharing among black, hispanic infants

2013-10-01

The proportion of infants bed sharing with caregivers increased between 1993 and 2010, especially among black and Hispanic families, according to a study published by JAMA Pediatrics, a JAMA Network publication. While infant bed sharing is a common practice in many countries, strong associations between the practice and sudden infant death syndrome have been established, according to the study background. The American Academy of Pediatrics recommends that infants share a room with their parents but not a bed for sleeping to prevent sleep-related infant deaths. The study ...

New study shows blood test detected cancer metastasis

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: